Coya Therapeutics price target raised to $14 from $11 at Chardan

Chardan analyst Keay Nakae raised the firm’s price target on Coya Therapeutics to $14 from $11 and keeps a Buy rating on the shares following the Q4 report. Management has refined the company’s development pipeline, which will now focus of development of COYA 302, “pipeline in a product” targeting multiple neurodegenerative diseases, the analyst tells investors in a research note.